EP1708987B1 - L-(-)-moprolol l-(+)-tartrate - Google Patents

L-(-)-moprolol l-(+)-tartrate Download PDF

Info

Publication number
EP1708987B1
EP1708987B1 EP05701093A EP05701093A EP1708987B1 EP 1708987 B1 EP1708987 B1 EP 1708987B1 EP 05701093 A EP05701093 A EP 05701093A EP 05701093 A EP05701093 A EP 05701093A EP 1708987 B1 EP1708987 B1 EP 1708987B1
Authority
EP
European Patent Office
Prior art keywords
moprolol
tartrate
pharmaceutical composition
salt
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05701093A
Other languages
German (de)
French (fr)
Other versions
EP1708987A1 (en
Inventor
Mario Pinza
Caterina Maugeri
Nicola Cazzolla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority to SI200531291T priority Critical patent/SI1708987T1/en
Priority to PL05701093T priority patent/PL1708987T3/en
Publication of EP1708987A1 publication Critical patent/EP1708987A1/en
Application granted granted Critical
Publication of EP1708987B1 publication Critical patent/EP1708987B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid

Definitions

  • the present invention thus relates to a method for preparing L-(-)-moprolol L-(+)-tartrate (2:1), characterized in that it includes the addition of L-(+)-tartaric acid, dissolved in a suitable organic solvent, to L-(-)-moprolol, also dissolved in a suitable organic solvent, in a 2:1 molar ratio.
  • the pharmaceutical composition according to the present invention may comprise other pharmacologically active ingredients whose simultaneous administration is useful.
  • the first group was treated with 0.1 ml of the first test solution three times a day for fifteen days.
  • the second group was treated with 0.1 ml of the second test solution three times a day for fifteen days.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Detergent Compositions (AREA)

Abstract

L-(-)-moprolol L-(+)-tartrate salt (2:1), method for preparing it and pharmaceutical composition comprising it.

Description

  • The present invention relates to L-(-)-moprolol L-(+)-tartrate (2:1), to a method for preparing it and to a pharmaceutical composition for ophthalmic use comprising it.
  • IT 1 113 029 describes a process for separating the two optical isomers of moprolol.
  • EP-A-0 118 940 describes the use of L-(-)-moprolol or a pharmaceutically acceptable acid-addition salt thereof to produce a fluid ophthalmic composition for treating glaucoma. The pharmaceutically acceptable acid-addition salt specifically illustrated and tested in the said document is the hydrochloride.
  • It has now been found that the L-(+)-tartrate shows better local tolerability than the hydrochloride.
  • In a first aspect, the present invention thus relates to L-(-)-moprolol L-(+)-tartrate (2:1).
  • The salt L-(-)-moprolol L-(+)-tartrate (2:1) is readily prepared via known techniques, for instance the addition of L-(+)-tartaric acid, dissolved in a suitable organic solvent, to L-(-)-moprolol base, also dissolved in a suitable organic solvent, in a 2:1 molar ratio. The salt thus formed (L-(-)-moprolol L-(+)-tartrate (2:1)) is then isolated via known techniques including the precipitation of the salt and its filtration or via removal of the solvents by evaporation.
  • In one preferred embodiment, the abovementioned organic solvent is ethyl alcohol and the salt is precipitated from the acetone solution via addition of ethyl ether.
  • In a second aspect, the present invention thus relates to a method for preparing L-(-)-moprolol L-(+)-tartrate (2:1), characterized in that it includes the addition of L-(+)-tartaric acid, dissolved in a suitable organic solvent, to L-(-)-moprolol, also dissolved in a suitable organic solvent, in a 2:1 molar ratio.
  • By virtue of its better local tolerability, L-(-)-moprolol L-(+)-tartrate is found to be particularly useful for ophthalmic use.
  • In a third aspect, the present invention thus relates to a pharmaceutical composition for ophthalmic use, characterized in that it comprises L-(-)-moprolol L-(+)-tartrate (2:1) together with at least one pharmaceutically acceptable vehicle.
  • Typical examples of pathological conditions that may find benefit from treatment with a pharmaceutical composition according to the present invention are ocular hypertension and glaucoma.
  • Preferably, the pharmaceutical composition according to the present invention will be in the form of a gel, an ointment or eyedrops and may also include other vehicles suitable for ophthalmic use, for instance ethylene glycol, PEG, carboxymethylcellulose, mannitol, sorbitol, poloxamers, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and the like.
  • The composition may also comprise other conventional ingredients such as: preserving agents, stabilizers; surfactants, buffers, salts for controlling the osmotic pressure, emulsifiers and the like.
  • If required for particular therapeutic uses, the pharmaceutical composition according to the present invention may comprise other pharmacologically active ingredients whose simultaneous administration is useful.
  • The amount of L-(-)-moprolol L-(+)-tartrate in the pharmaceutical composition of the present invention may vary within a wide range depending on known factors, for instance the particular type of disease to be treated, the seriousness of the disease and the number of daily administrations. However, a person skilled in the art may easily and routinely determine the optimum amount.
  • Typically, the amount of L-(-)-moprolol in the pharmaceutical composition of the present invention is between 0.01% and 20% by weight and even more preferably between 1% and 8% by weight.
  • The dosage forms of the pharmaceutical composition of the present invention may be prepared according to techniques that are well known to pharmaceutical chemists, including mixing, dissolution, sterilization and the like.
  • The examples that follow are given to illustrate the present invention without, however, limiting it.
    • Example 1 Preparation of L-(-)-moprolol L-(+)-tartrate (2:1) Step a)
  • 2N sodium hydroxide solution was added dropwise to a solution of L-(-)-moprolol hydrochloride (10 g) in water (100 ml) with stirring, until no further precipitate was formed.
  • The precipitate was extracted with dichloromethane (100 ml). The organic phase was separated out and dried over sodium sulphate. Finally, the dichloromethane was removed by evaporation.
  • The solid residue thus obtained consisted of L-(-)-moprolol base (9.1 g).
    • Step b)
  • A solution of L-(+)-tartaric acid (1.57 g; 0.01 mol) in absolute ethanol (15 ml) was added to a solution of L-(-)-moprolol base (5.0 g; 0.02 mol) in hot absolute ethanol (30 ml).
  • After stirring the solution at 60°C for 10 minutes, ethyl ether was added until precipitation was complete. The precipitate thus obtained (very hygroscopic) was separated out by decantation and crystallized from absolute ethanol (30 ml) to give the desired product (5.2 g).
    m.p. = 135°C. [α] = -1.1 (c = 5 in H2O)
    Elemental Analysis
    For C30H48N2O12 C H N
    Calculated 57.31 7.70 4.46
    Found 57.16 7.79 4.38
    • Test 1 Ocular Tolerability
  • Two aqueous solutions were used.
  • The first contained 1% by weight of L-(-)-moprolol hydrochloride (corresponding to 0.87% by weight of L-(-)-moprolol). The second contained 1.14% by weight of L-(-)-moprolol L-(+)-tartrate (2:1) (corresponding to 0.87% by weight of L-(-)-moprolol).
  • 12 male rabbits (New Zealand White) with an average weight of 2 kg and an average age of ten months were used, divided into two groups of six rabbits each. The first group was treated with 0.1 ml of the first test solution three times a day for fifteen days. The second group was treated with 0.1 ml of the second test solution three times a day for fifteen days.
  • The tolerability was evaluated according to J. Draize et al., Pharmacol. Exp. Ther., 83, 377-390 (1944). The results are shown in Table 1 below. Table 1
    Before the first application After the last application
    L-(-)-moprolol hydrochloride L-(-)-moprolol L-(+)-tartrate
    Conjunctiva Reddening 1 0
    Swelling 2 0
    Lachrymation 2 1
    Iris 0 0
    Cornea Opacity 0 0
    Area of the cornea affected by opacity 0 0
    Total Score 5 1

Claims (9)

  1. L-(-)-moprolol L-(+)-tartrate salt (2:1).
  2. Pharmaceutical composition for ophthalmic use, characterized in that it comprises L-(-)-moprolol L-(+)-tartrate (2:1) together with at least one pharmaceutically acceptable vehicle.
  3. Pharmaceutical composition according to Claim 2, characterized in that it is in the form of a gel, an ointment or eyedrops.
  4. Pharmaceutical composition according to Claim 2 or 3, characterized in that the amount of L-(-)-moprolol is between 0.01 % and 20% by weight.
  5. Pharmaceutical composition according to Claim 2 or 3, characterized in that the amount of L-(-)-moprolol is between 1% and 8% by weight.
  6. Process for preparing L-(-)-moprolol L-(+)-tartrate (2:1), characterized in that it includes the addition of L-(+)-tartaric acid, dissolved in a suitable organic solvent, to L-(-)-moprolol base, also dissolved in a suitable organic solvent, in a 2:1 molar ratio.
  7. Process according to Claim 6, characterized in that the salt thus formed is isolated via precipitation and filtration.
  8. Process according to Claim 6 or 7, characterized in that the abovementioned organic solvent is ethyl alcohol.
  9. Process according to Claim 8, characterized in that the salt is precipitated from the ethanolic solution via addition of ethyl ether.
EP05701093A 2004-01-30 2005-01-14 L-(-)-moprolol l-(+)-tartrate Active EP1708987B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI200531291T SI1708987T1 (en) 2004-01-30 2005-01-14 L-(-)-moprolol l-(+)-tartrate
PL05701093T PL1708987T3 (en) 2004-01-30 2005-01-14 L-(-)-moprolol l-(+)-tartrate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000145A ITMI20040145A1 (en) 2004-01-30 2004-01-30 L-MOPROLOLO LPIU 'TARTRATO
PCT/EP2005/000560 WO2005075408A1 (en) 2004-01-30 2005-01-14 L-(-)-moprolol l-(+)-tartrate

Publications (2)

Publication Number Publication Date
EP1708987A1 EP1708987A1 (en) 2006-10-11
EP1708987B1 true EP1708987B1 (en) 2011-03-16

Family

ID=34835572

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05701093A Active EP1708987B1 (en) 2004-01-30 2005-01-14 L-(-)-moprolol l-(+)-tartrate

Country Status (20)

Country Link
US (1) US7524886B2 (en)
EP (1) EP1708987B1 (en)
JP (1) JP4646922B2 (en)
KR (1) KR101122173B1 (en)
CN (1) CN100480232C (en)
AT (1) ATE502003T1 (en)
AU (1) AU2005211458B2 (en)
BR (1) BRPI0507150A (en)
CA (1) CA2550302C (en)
DE (1) DE602005026908D1 (en)
DK (1) DK1708987T3 (en)
EA (1) EA200601402A1 (en)
ES (1) ES2361518T3 (en)
HK (1) HK1093962A1 (en)
IL (1) IL176280A (en)
IT (1) ITMI20040145A1 (en)
PL (1) PL1708987T3 (en)
PT (1) PT1708987E (en)
SI (1) SI1708987T1 (en)
WO (1) WO2005075408A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1211589A (en) * 1968-08-06 1970-11-11 Ici Ltd Enantiomer isolation process
IT1113029B (en) 1979-03-01 1986-01-20 Simes PROCESS FOR THE SEPARATION OF THE TWO OPTICAL ISOMERS OF MOPROLOL AND PHARMACEUTICAL COMPOSITIONS OF THE LEVOGIRO ANTIPOD
IT1163107B (en) * 1983-02-15 1987-04-08 Simes PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN GLAUCOMA TREATMENT
DE3544172A1 (en) * 1985-12-13 1987-06-19 Lentia Gmbh NEW CRYSTALLINE SALTS OF ARYLOXY PROPANOLAMINES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
AR030414A1 (en) * 2000-04-03 2003-08-20 Astrazeneca Ab PHARMACEUTICAL COMBINATION THAT INCLUDES A BLOCKING BETA AND A REDUCED HMG-COA INHIBITOR, PHARMACEUTICAL FORMULATION, TRANSPORTABLE PARTS EQUIPMENT, USE OF THIS COMBINATION AND THIS FORMULATION TO PREPARE MEDICATIONS

Also Published As

Publication number Publication date
ITMI20040145A1 (en) 2004-04-30
HK1093962A1 (en) 2007-03-16
KR101122173B1 (en) 2012-03-15
CA2550302A1 (en) 2005-08-18
CN1910138A (en) 2007-02-07
JP2007519661A (en) 2007-07-19
ATE502003T1 (en) 2011-04-15
WO2005075408A1 (en) 2005-08-18
CN100480232C (en) 2009-04-22
EA200601402A1 (en) 2006-12-29
US20080015258A1 (en) 2008-01-17
DK1708987T3 (en) 2011-06-27
ES2361518T3 (en) 2011-06-17
CA2550302C (en) 2012-04-24
AU2005211458A1 (en) 2005-08-18
PL1708987T3 (en) 2011-08-31
AU2005211458B2 (en) 2010-06-24
IL176280A (en) 2010-12-30
KR20070000451A (en) 2007-01-02
IL176280A0 (en) 2006-10-05
PT1708987E (en) 2011-05-31
SI1708987T1 (en) 2011-06-30
JP4646922B2 (en) 2011-03-09
EP1708987A1 (en) 2006-10-11
BRPI0507150A (en) 2007-06-26
US7524886B2 (en) 2009-04-28
DE602005026908D1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
EP1884234B1 (en) Prophylactic or therapeutic agent for corneal and conjunctival disorder
EP1679074B1 (en) Therapeutic agent for keratoconjunctive disorder
CZ302483B6 (en) Aqueous solution containing epinastine
WO2021031999A1 (en) Prodrug of mycophenolic acid and method for preparation thereof
EP1708988B1 (en) Ibopamine maleate, method for preparing it and pharmaceutical compositions containing it
EP1708987B1 (en) L-(-)-moprolol l-(+)-tartrate
CA2152191C (en) Therapeutic agent for glaucoma and ocular hypotensive agent
EP1480970B1 (en) Quinoline derivatives
MXPA06008528A (en) L-(-)-moprolol l-(+)-tartrate
MXPA06008531A (en) Ibopamine maleate, method for preparing it and pharmaceutical compositions containing it
KR20060136421A (en) L-(-)-morphrolol L-(+)-tartarate
US6953813B1 (en) 2-Aminotetralin derivatives for the therapy of glaucoma
EP1448219B1 (en) Antiglaucomatous agent and use thereof
WO2013114397A2 (en) Pharmaceutically acceptable salt of brinzolamide and composition thereof
US20040067891A1 (en) Therapeutic and/or preventive agents for diseases due to retinal ischemia
JPH07330604A (en) Curing agent for xerophthalmia
EP1757601B1 (en) Quinoline derivatives and their use in glaucoma and myopia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060623

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LV

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20060622

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1093962

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LV

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602005026908

Country of ref document: DE

Date of ref document: 20110428

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005026908

Country of ref document: DE

Effective date: 20110428

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. AG PATENT- UND MARKENANWAELTE VSP

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20110524

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2361518

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20110617

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20110401218

Country of ref document: GR

Effective date: 20110614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110316

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1093962

Country of ref document: HK

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20110316

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110316

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 9498

Country of ref document: SK

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E011032

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110716

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20111219

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005026908

Country of ref document: DE

Effective date: 20111219

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: EE

Payment date: 20161222

Year of fee payment: 13

Ref country code: MC

Payment date: 20161227

Year of fee payment: 13

Ref country code: LU

Payment date: 20161229

Year of fee payment: 13

Ref country code: NL

Payment date: 20161228

Year of fee payment: 13

Ref country code: CH

Payment date: 20161229

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20161229

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20170117

Year of fee payment: 13

Ref country code: FR

Payment date: 20170120

Year of fee payment: 13

Ref country code: SE

Payment date: 20170123

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20170116

Year of fee payment: 13

Ref country code: BE

Payment date: 20161228

Year of fee payment: 13

Ref country code: DK

Payment date: 20170110

Year of fee payment: 13

Ref country code: GB

Payment date: 20170123

Year of fee payment: 13

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E005497

Country of ref document: EE

Effective date: 20180131

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20180131

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20180201

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180131

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180131

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180114

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180114

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180115

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20180928

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180131

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180131

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180201

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180114

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180114

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180131

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180806

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20181228

Year of fee payment: 15

Ref country code: SK

Payment date: 20181219

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20190121

Year of fee payment: 15

Ref country code: DE

Payment date: 20190123

Year of fee payment: 15

Ref country code: ES

Payment date: 20190226

Year of fee payment: 15

Ref country code: CZ

Payment date: 20190114

Year of fee payment: 15

Ref country code: PL

Payment date: 20190102

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20190122

Year of fee payment: 15

Ref country code: SI

Payment date: 20181221

Year of fee payment: 15

Ref country code: GR

Payment date: 20190123

Year of fee payment: 15

Ref country code: HU

Payment date: 20190116

Year of fee payment: 15

Ref country code: TR

Payment date: 20190108

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180131

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20190109

Year of fee payment: 15

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005026908

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 502003

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200114

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 9498

Country of ref document: SK

Effective date: 20200114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200114

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200114

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200801

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200114

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200814

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200806

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200115

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200114

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200115

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20201030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200114

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20210603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200114